The glycosyl moiety–enriched Rg3-lipo drug delivery system selectively inhibited tumor cell proliferation and accumulation of MDSCs by targeting Glut1 and Glut3, respectively, promoting an enhanced antitumor immune response. The gene discussed is SLC2A3; the disease is neoplasm.